The OCS team discuss the challenges of developing PARP inhibitors, Synthetic lethality and the use of PARP inhibitors in clinical practice.
Dr Tony Williams. MA, MB, BS, FRCP
Dr Williams is an experienced drug developer with experience of large pharma in the areas of early-stage development in oncology. He is an oncologist by training (Cambridge and UCL) and has worked in oncology clinical research for over 20 years, with considerable experience in ovarian, prostate, metastatic breast, and pancreatic cancer with recent experience with PARPi-combinations. He has translational experience of the role of markers, both predictive and prognostic, in the early stage of development to effectively assess PARPi and design phase 3 studies. He is also interested in patient reported outcomes, which has become important in decisions involving dose escalation in early oncology clinical studies.
Dr Chee Gee See. PhD
Dr See is a translational medicine leader with over 30 years’ experience in pharma (GSK & Roche), small biotechs and academia. He has extensive industry experience in developing oncology drugs and was the biomarker and experimental medicine leader in the Phase 3 ToGA study when the indication for Herceptin was extended from breast cancer to gastric and esophageal cancer. He is experienced in all clinical and preclinical phases and also led the early development of a prostate cancer drug from target identification to hit identification. He has expertise in shaping clinical biomarker strategies that lead to companion diagnostic development and understanding mechanisms of disease resistance so we can map the optimal next-generation clinical development.